DS Healthcare Announces Results From New Clinical Study

Pompano Beach, July 17, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer ofpersonal care products, announced today clinical results of a studyshowing that its Spectral.DNC-S containing a compound sourced as abyproduct of pine production is effective in the promotion ofhealthy hair and in the cessation of thinning hair in males.

Spectral.DNC-S addresses the $3.5 billion spent per year byAmericans attempting to treat their hair loss. Spectral.DNC-S is acompletely new innovation for the treatment of thinning hair. Afterseveral years of exhaustive research, DS Laboratories hasdiscovered a compound from a natural source which mimic and exceedthe activity of pharmaceutical treatments but with greatly reducedside effects. This compound, sourced from pine bark, is believed toact by opening ion channels in cells. It is DS Healthcare's mostpotent and advanced formulation to date and provides an entirelynew mechanism of action. 

The double-blind trial was conducted at Miami Dade MedicalCenter in Miami, Florida. The subjects were between the ages of 25and 55 years and had been experiencing active thinning hair.Clinical assessment of scalps of volunteers showed that 85% ofsubjects had an increase in hair density and 17% had a dramaticimprovement. 11% of subjects had no response.

"These clinical results provide further evidence that there aremany variables involved in overall hair and scalp health, and thisin turn forms the cornerstone of our multivariate approach totherapy. We believe this product line holds great promise for broadcommercial success in global markets where we currently havedistribution channels," stated DS Healthcare Group President andCEO, Daniel Khesin.  

About DS Healthcare Group

DS Healthcare Group, Inc. leads in the development ofbiotechnology for topical, and nutritional therapies. It marketsthrough online and specialty retailers, distributors, cosmeticswholesalers and salons. Its brands include DS Laboratories( www.DSLaboratories.com),Sigma Skin ( www.SigmaSkin.com), PolarisResearch Laboratories ( www.PolarisReserachLabs.com)and Pure Guild ( www.ThePureGuild.com).

Forward-Looking Statements:

Except for statements of historical fact, the matters discussedin this press release are forward-looking and made pursuant to theSafe Harbor provisions of the Private Securities Litigation ReformAct of 1995. "Forward-looking statements" describe futureexpectations, plans, results, or strategies and are generallypreceded by words such as "future," "plan" or "planned," "expects,"or "projected." These forward-looking statements reflect numerousassumptions and involve a variety of risks and uncertainties, manyof which are beyond the company's control that may cause actualresults to differ materially from stated expectations. These riskfactors include, among others, limited operating history,difficulty in developing and marketing products, intensecompetition and additional risks factors as discussed in reportsfiled by the company with the Securities and Exchange Commission,which are available at http://www.sec.gov.
CONTACT: Contact:         Laurel Moody         Corporate Profile         1.646.810.0608